Developing Quality Medications for Eye Care
Therapeutic Vision, Inc. is a small company located in Omaha, Nebraska. We are focused on the development of pharmaceuticals primarily for the companion animal market and eventually for humans. We are developing age-related and diabetic therapies for the preservation of vision and the prevention of neurodegeneration. As experts in cataract development, we offer contract toxicological research services to evaluate the effects of drugs on lens opacity and cataract formation.
Our mission is to develop unique drugs that greatly benefit not only animals but also humans.
Executive Team and Consultants
Peter F. Kador, Ph.D., F.A.R.V.O., F.A.O.P.T.
President and CEO
Peter Kador is the Founder, President/CEO. After 25 years at the National Eye Institute, N.I.H. he retired as Chief of the Lab. of Ocular Therapeutics. He then served as Professor and (now Professor Emeritus) of Pharmaceutical Sciences and Professor of Ophthalmology at the University of Nebraska Medical Center. He is an internationally recognized vision scientist and expert.
Suellen Kador, B.A.
Suellen Kador is the corporation secretary/treasurer. She has 31 years of experience as a high school chemistry teacher and 6 years as a laboratory instructor at the University of Nebraska at Omaha Chemistry Department.
Robert Munger, D.V.M., D.A.C.V.O.
Senior Veterinary Ophthalmologist.
Bob Munger is the Senior Veterinary Ophthalmologist, Founder of Animal Ophthalmology Clinic, Ltd., Dallas TX, Ophthalmic Toxicology Consultant, and past-President, the American College of Veterinary Ophthalmologists.
Manley A. Paulos, Ph.D.
Regulatory Affairs and Clinical Director
Manley A. Paulos serves as Regulatory Affairs and Clinical director. He has over 30 years of Pharmaceutical Industry experience, including positions as Medical Director (Merrell-Dow): Director, Clinical and Regulator Affairs (Bayer) President, Premier Research (CRO), and Komodo Pharmaceutical Services (drug delivery systems manufacturing).
Karen Blessing, B.S., R.V.T.
Karen Blessing is the Research Coordinator. Ms. Blessing has assisted Dr. Kador on his research projects at both the National Eye Institute and at the University of Nebraska Medical Center and now coordinates the Kinostat® trial.
Vince Bellavia, B.Sci., M.B.A.
Vince Bellavia serves as the Business Consultant. Mr. Bellavia is President and CEO of AVENTIX Animal Health Corp. a Canadian owned and operated veterinary product marketing and distribution company.
William E. Thompson, B.A., C.P.A.
Financial and Business Advisor
William E. Thompson is the financial advisor. He is Managing Partner of Thompson, Cooling & Associated LLC. and specializes in small business consulting, accounting, and income tax. He was a consultant with Deloitte & Touche in their small business consulting group on IPO's general ledger conversions, and third party reviews.
Richard J. Salvi, Ph.D.
Richard J. Salvi the SUNY Distinguished Professor of Communicative Disorders and Sciences, is the co-founder and director of the University at Buffalo's Center for Hearing and Deafness, one of the country's foremost hearing research groups. He is a collaborator of Dr. Kador.
L. David Waterbury, Ph.D.
Advisor and Senior Scientist
L. David Waterbury is an expert in the treatment of inflammatory diseases, free radicals and ocular pharmacology who is accomplished in bridging the gap between bench-top and the clinic. As Director of Raven Biosolutions LLC, he has proven success in drug development as demonstrated by publications, U.S. patents issued, and role of selecting drugs for clinical trials.
Peter Oates, Ph.D.
Peter Oates is a retired Research Fellow of Diabetes Translational Pharmacology at Pfizer Global R&D at Groton, C.T. with extensive experience in diabetic complications. He is currently Chief Scientific Officer at Oates Biomedical Consulting LLC. He is also longtime collaborator of Dr. Kador.
Marjorie Lou, Ph.D., F.A.R.V.O.
Marjorie Lou is the retired Willa Cather Professor of Biomedical Sciences at the University of Nebraska-Lincoln. Prior to this position. Dr. Lou was a Research Director at Alcon Laboratories, Ft. Worth, TX. She is a long-time collaborator of Dr. Kador and an expert on the role of oxidation in cataract formation.
Milton Wyman, D.V.M., M.S., D.A.V.C.O.
Senior Ophthalmologist 2003-2021
Former Professor and Associate Dean, The Ohio State University College of Veterinary Medicine. As consultant to Kador at the National Eye Institute Dog Retinopathy Project, he recognized the potential of ARIs for treating cataracts in diabetic dogs. At Milt’s urging Therapeutic Vision, Inc. was started, and the successful eye drop known as Kinostat was developed. Milt served as a P.I. and Clinical Trial Director from TVI’s inception and has been one of the company’s most knowledgeable and trusted members of the TVI team. His passing in the fall of 2021 has left Therapeutic Vision, as well as us personally, missing a dear friend.